← All trials
NCT03690011
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2019
- Primary completion
- May 1, 2023
- Completion date
- May 1, 2038
- First posted
- —
- Last posted
- —
- Enrollment
- 21
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Baylor UniversityLead sponsor
- Baylor UniversityReponsible party - principal investigator
- Baylor UniversityOverall official - principal investigator
- Baylor UniversityCollaborator
- Methodist Cancer Center, Houston, TexasCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.